Skip to content

Devil Vaccine Research

Our vision is to create a vaccine that will give Tasmanian devils lifelong protection from Devil Facial Tumour Disease.

A new era in the fight to secure the future for the Tasmanian devil has commenced. Creation of a vaccine will ensure a disease-free future for the Tasmanian devil living where it belongs, in the wild.

With losses of well over 80 percent of Tasmanian devils through the contagious cancer - Devil Facial Tumour Disease (DFTD) - the future for the devil looked bleak.

However, during the past ten years of collaborative research and conservation programs, progress has been extraordinary. An Insurance Population has been established, the impact of the disease in the wild is monitored regularly and disease-free facilities to hold the species in wild and semi-wild populations have been built.

Investigation into the nature of DFTD and determining paths to halt the spread of the disease has progressed significantly. Researchers are now in the position to develop a vaccine, rekindling hopes of saving this iconic species in the wild.

The ambitious goal of vaccine development is now a reality. The next step is to validate the research and trial and refine the vaccine with 60 wild Tasmanian devils over the next three years. This research is a collaborative world-wide effort, being led by the University of Tasmania’s Menzies Institute for Medical Research.

Right now we have an historic opportunity to take a proactive role in securing the future for the Tasmanian Devil.

To learn more we encourage you to view this amazing video – Devil Vaccine Research.